Prognostic relevance of the metastatic localisation in patients with stage IV NSCLC results of a prospective epidemiological study;Prognostische Relevanz der Metastasenlokalisation bei nicht kleinzelligem Bronchialkarzinom im Tumorstadium IV Ergebnisse einer prospektiven epidemiologischen Studie

Pneumologie

Volumn 64, Issue 11, 2010, Pages 679-685

  Blankenburg, T ^a   Gottschlich, B ^a   Schutte W ^a   Neef, H ^b   Haerting, J ^b  

^a Hospital Martha Maria Halle Dölau   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL STUDY; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GERMANY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 78249268287     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1244238     Document Type: Article

References (28)

1. Parkin M, Pisani P, Ferlay J. Global cancer statistics. Cancer J Clin 1999 49 33-64
2. Reis L AG, Kosary C L., Hankey B F. et al. SEER cancer statistics review, 19731996. Bethesda, MD National Cancer Institute 1999
3. Ihde D C. Chemotherapy of Lung Cancer. N Engl J Med 1992 327 1434-1441
4. DeVita V T., Hellman S, Rosenberg S A. Cancer: principles and practice of oncology. Philadelphia, PA J.B. Lippincott 1993
5. Bonomi P, Kim K, Fairclough D, Cella D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 18 623-31
6. Ries L, Elsner M, Kosary C. Cancer statistics review 19752002. Bethesda MD National Cancer Institute 2005
7. Scagliotti G V., Parikh P, Pawel J von et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 26 3543-3551
8. Shaw G L., Gazdar A F., Phelps R et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J cell biochem 1996 24 173-185
9. Coebergh J WW, Janssen-Heijnen M LG, Louwman W J. et al. Cancer incidence, care and survival. Eindhoven Cancer Registry (IKZ) 2001
10. Gregor A, Thomson C S., Brewster D H. et al. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 2001 56 212-217
11. Miller V A., Kris M G. et al. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced NonSmall-Cell Lung Cancer. J Clin Oncol 2004 22 1103-1109
12. Thomas M, Baumann M, Deppermann M et al. Empfehlungen zur Therapie des Bronchialkarzinoms. Gemeinsame Empfehlung der Deutschen Gesellschaft für Pneumologie (DGP), der Deutschen Gesellschaft für Radioonkologie (DEGRO), der Deutschen Gesellschaft für Thoraxchirurgie (DGT) und der Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft (AIO). Pneumologie 2002 56 113-131
13. Shepherd F A. Treatment of advanced non-small cell lung cancer. Semin in oncol 1994 21 7-18
14. Jeremic B A., Dagovic B A., Nikolic N A. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol 2003 129 114-122
15. Albain K S., Crowley J J., LeBlanc M, Livingston R B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991 9 1618-1626
16. Nakajima, Furuse A, Oka T, Kohno T et al. Excellent Survival in a Subgroup of Patients With Intrapulmonary Metastasis of Lung Cancer. Ann Thorac Surg 1996 61 158-163
17. Jacot W, Quantin X, Boher J-M et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors. British Journal of Cancer 2001 84 903-909
18. Luketich J L., Burt M E. Does Resection of Adrenal Metastases From NonSmall Cell Lung Cancer Improve Survival? Ann Thorac Surg 1996 62 1614-1616
19. ASCO Special Article: American society of clinical oncology treatment of unresectable Nonsmall cell lung cancer guideline: update 2003. J Clin Oncol 2004 22 330-353
20. Schiller J H. Current Standards of Care in Small-Cell and Non-Small. Cell Lung Cancer. Oncology 2001 61 3-13
21. Silvestri G A., Tanoue L T., Margolis M L. et al. The Non-invasive Staging of Non-small Cell Lung Cancer The Guidelines. CHEST 2003 123 147-156
22. Pieterman R M., van Putten J WG, Meuzelaar J J. et al. Preoperative staging of non-small-cell lung cancer with positronemission tomography. N Engl J Med 2000 343 254-261
23. Saunders C AB, Dussek J E., ODoherty M J. et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999 67 790-797
24. British Thoracic Society, Society of Thoracic Surgeons of Great Britain, Ireland Working Party. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001 56 89-106
25. Schwartz L H., Ginsberg M S., Burt M E. et al. MRI as alternative to CT guided biopsy of adrenal masses in patients with lung cancer. Ann Thorac Surg 1998 65 193-197
26. Porte H L., Ernst O J., Delebecq T et al. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small cell lung cancer? Eur J Cardio Thorac Surg 1999 15 597-601
27. Tammemagi C M., Neslund-Dudas C, Simoff M et al. In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 2004 57 597-609
28. Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010 64 S23-S156